Amarantus BioSciences Awarded US Patent Protecting Composition of Matter for MANF
January 11 2012 - 9:42AM
Business Wire
Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology
company developing MANF, a first-in-class disease–modifying
therapeutic protein, today announced U.S. Patent Number 8,084,425
has been issued for MANF entitled, Dopaminergic Neuronal
Survival-Promoting Factors and Uses Thereof. This patent covers the
discovery of MANF and its composition of matter and complements the
Company’s existing portfolio of issued patents and pending patent
applications. The key claim allowed under the patent is as follows:
A pharmaceutical composition comprising: (i) a substantially
purified polypeptide comprising the sequence of SEQ ID NO: 2
(MANF); and (ii) a carrier that is pharmaceutically acceptable for
administration to the central nervous system.
“The issuance of this new patent validates the novelty of the
science Amarantus is producing and validates the tremendous work
our scientific team has put forth over the last several years,”
said Gerald Commissiong, President and CEO. “We hope to turn this
groundbreaking discovery into a game-changing therapy when we
ultimately embark on human clinical development for the treatment
of Parkinson’s disease and other disorders of the Central Nervous
System. We intend to continue intellectual property prosecution for
MANF in other disease states as well.”
About MANF (Mesencephalic-Astrocyte-derived Neurotrophic
Factor)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a
protein that corrects protein misfolding, one of the major causes
of apoptosis (cell death). This property provides a compelling
rationale for the research and development of MANF-based products
as therapeutics for human disease. The lead MANF product
development effort is centered on a therapy for Parkinson's
disease, currently funded by a research grant from the Michael J.
Fox Foundation for Parkinson’s Research. The Company also owns an
inventory of 88 cell lines referred to as “PhenoGuard Cell Lines.”
MANF was the first therapeutic protein discovered from a PhenoGuard
Cell Line. It is anticipated that additional therapeutic proteins
useful for various therapeutic approaches to the Central Nervous
System will be identified from the Company’s inventory of
PhenoGuard Cell Lines.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a California-based
development-stage biotechnology company founded in January 2008.
The Company has a focus on developing certain biologics surrounding
the intellectual property and proprietary technologies it owns
to treat Parkinson’s disease and other human diseases. The Company
owns the intellectual property rights to a therapeutic protein
known as Mesencephalic-Astrocyte-derived Neurotrophic Factor
("MANF"). For further information please visit
www.amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about the possible benefits of MANF therapeutic applications and/or
advantages presented by Amarantus’ PhenoGuard technology, as well
as statements about expectations, plans and prospects of the
development of Amarantus' new product candidates. These
forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including the risks that the
anticipated benefits of the therapeutic drug candidates or
discovery platforms, as well as the risks, uncertainties and
assumptions relating to the development of Amarantus' new product
candidates, including those identified under "Risk Factors" in
Amarantus' most recently filed Annual Report on Form 10-K and
Quarterly Report on Form 10-Q and in other filings Amarantus
periodically makes with the SEC. Actual results may differ
materially from those contemplated by these forward-looking
statements Amarantus does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this
presentation.
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From May 2024 to Jun 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Jun 2023 to Jun 2024